By Henry Ehrlich
We are very grateful to the organizers of the Food Allergy Blogger Conference for many reasons, but at the top of the list is the introduction to Dr. David Stukus who has very generously shared his medical and writing skills with us on short notice. First it was his views on the special challenges of treating asthma with Medicaid patients. Then it was the time he spent answering questions about his own research into what internists and other general practitioners don’t know about food allergies. Just a few weeks ago he wrote about the challenge of persuading patients, caregivers, emergency medical personnel, and doctors that injectable epinephrine is the best way to treat anaphylaxis.
Thus, it was a gift when the above Tweet appeared after the presentation of the LEAP study at AAAAI. The pixels were barely dry on the Tweet when we reached out. Who better to analyze the study for us than our own new best friend, Dr. Stukus? The result is a spectacular analysis of the promise and possible pitfalls of this landmark study. Thanks, Dave—this is just what the editor ordered.
Amen.